Gerber Kawasaki Wealth & Investment Management Editas Medicine, Inc. Transaction History

Gerber Kawasaki Wealth & Investment Management

$2.16 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$26.55 - $40.57 $68,499 - $104,670	-2,580 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $101,316 - $188,185	2,580 New	2,580 $105,000
Q3 2018 Nov 06, 2018	SELL	$27.65 - $38.39 $171,568 - $238,209	-6,205 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$29.84 - $44.08 $185,157 - $273,516	6,205 New	6,205 $205,000

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

Black Rock Inc. New York, NY

7.78M
Shares

$9.88 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$8.48 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.9M
Shares

$6.22 Million
0.62% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.35M
Shares

$4.26 Million
0.01% of portfolio
State Street Corp Boston, MA

2.46M
Shares

$3.13 Million
0.0% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $87.3M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gerber Kawasaki Wealth & Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Gerber Kawasaki Wealth & Investment Management with notifications on news.

Account